Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the Article8th Circuit ruling
4 storiesS-1 public filing
1 storyOCC reply on motion to dismiss or transfer Nov 2
1 storyHouse Oversight document deadline Nov 9
1 storyTrade truce expiry Nov 10
1 storySenate committee report Nov 20
Ten states told an Oregon federal court that three Supreme Court petitions will not answer whether the OCC's escrow rules are lawful, and that a pause would let banks stop paying interest on escrow balances now.
The FTC ordered Walmart, Target, Uber and six other companies to show how personal data sets individual prices and gig pay, opening a record that could outlast next week's election.
HHS told the FDA not to enforce compounding rules against six unproven peptides, opening a prescription supply route that most of the agency's drug scientists opposed.
A JAMA study of the WISeR pilot in six states found epidural steroid injections fell about 15 percent and other targeted services about 20 percent, while the authors caution the data cannot show whether the care was necessary.
A House Oversight letter seeks records on how a proposed corporate form run by an AI agent would allocate liability, as Delaware weighs a 30-month sandbox that critics call a shield for AI companies.
The House passed a digital duty of care bill with an amendment barring services that foster a child's emotional dependence on a chatbot, sending the measure to a contested Senate fight.
The Supreme Court declined to let three cities intervene, leaving a Texas-DOJ consent judgment that vacated the 2024 administrative closure rule in force nationwide.
Retatrutide cut A1C by 2.2 points and weight by about 21 percent over 80 weeks, beating semaglutide in TRANSCEND-T2D-2, though the open-label design and a wider tolerability gap complicate the claim.
Skipton Building Society extended standard mortgage offer validity from six to nine months on October 27, a response to chains and legal delays rather than affordability.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Forrester's Q3 2026 Wave scores ten providers against twenty nine criteria, cutting the field's criteria count for the first time, while a vendor that owns its content finishes last equal.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article